BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE) Files An 8-K Financial Statements and Exhibits

BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE) Files An 8-K Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits

Story continues below


Boston Therapeutics, Inc. Exhibit
EX-4.1 2 s107284_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1   SECURITIES PURCHASE AGREEMENT   This Securities Purchase Agreement (this “Agreement”) is dated as of _______ __,…
To view the full exhibit click here

About BOSTON THERAPEUTICS, INC. (OTCMKTS:BTHE)

Boston Therapeutics, Inc. (BTI) is a pre-clinical and clinical-stage pharmaceutical company. The Company is focused on the development, manufacture and commercialization of carbohydrate-based therapeutic drugs and dietary supplements designed to address blood sugar management and inflammatory diseases. BTI-320 is its lead product candidate. BTI-320 is a Carbohydrate hydrolyzing Enzyme Inhibitor for treatment of patients with Type 2 diabetes. BTI-320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications, which is designed to reduce post-meal glucose elevation. BTI-320 is in Phase II clinical development. IPOXYN and OXYFEX are in pre-clinical stage of drug development. IPOXYN is indicated for lower limb vascular complications of diabetes. OXYFEX is indicated for veterinary ischemic tissue. It produces and sells SUGARDOWN, a non-systemic carbohydrate-based dietary food supplement to support post-meal blood glucose.

An ad to help with our costs